Background We assessed the effectiveness of dual antiplatelet therapy (DAPT) post elective
or urgent (ie, post acute coronary syndrome [ACS]) coronary artery bypass graft surgery …

The choice and duration of antiplatelet therapy for secondary prevention of coronary artery
disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet …

Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in
patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous …

Objectives The 30‐day clinical outcomes with prasugrel or ticagrelor were compared using a
US payer database in patients with acute coronary syndrome (ACS) undergoing …

Essentials• The comparative efficacy and safety of antiplatelet agents in 'real life'is not clear.•
We recruited acute coronary syndrome patients receiving percutaneous coronary …

Background Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients
with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions …

Whether newer P2Y12 inhibitors are more efficacious and safer than clopidogrel and
whether there is a superior one remain uncertain. We compared the effect of P2Y12 …

Background Limited data are available concerning differences in clinical outcomes for real-
life patients treated with ticagrelor versus prasugrel after percutaneous coronary intervention …

Background The newer oral P2Y12 receptor antagonists (ie prasugrel and ticagrelor) are
recommended over clopidogrel for patients with acute coronary syndrome (ACS) going for …

Abstract Background Prasugrel and Ticagrelor are emerging antiplatelet drugs that might
have the potential to replace currently used antiplatelet agents. Previous analyses …